First human trial launches for vaccine against recurring yeast infections

NCT ID NCT06190509

Ongoing ⭐️ VACCINE ⭐️ Sponsor: LimmaTech Biologics AG Source: ClinicalTrials.gov ↗

First seen Sep 30, 2025 · Last updated Apr 19, 2026 · Updated 22 times

Summary

This study is testing a new vaccine designed to prevent recurrent vaginal yeast infections (candidiasis). It is the first time the vaccine is being given to people. Researchers will check if it is safe, if it causes a good immune response, and if it reduces how often infections come back in women who frequently get them.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT VULVOVAGINAL CANDIDIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Aidport sp.z o.o.

Skórzewo, Poznan, 60-185, Poland
Femicare

Tienen, Tienen, 3300, Belgium
IN-VIVO Sp. z o.o.

Bydgoszcz, 85-048, Poland
MTZ Clinical Research powered by Pratia

Warsaw, 02-172, Poland
NZOZ Medem

Katowice, 40-301, Poland
Universitair Ziekenhuis Gent

Ghent, 9000, Belgium
Velocity Nova sp. z o.o

Lublin, 20-362, Poland

Conditions

Explore the condition pages connected to this study.

RECURRENT VULVOVAGINAL CANDIDIASIS